Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Negar Chooback"'
Autor:
Alan Nichol, Timothy Kong, A. Benny, Cheryl Ho, Lovedeep Gondara, Negar Chooback, I.M. Fraser, Shilo Lefresne
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e569-e570
Purpose/Objective(s) With modern therapies, the median survival of patients with brain metastases (BrM) from non-small cell lung cancer (NSCLC) with epidermal growth factor receptor mutation (EGFRm) may exceed 1-2 years. BrM directed therapies must t
Autor:
Lovedeep Gondara, Alan Nichol, Timothy Kong, Cheryl Ho, Shilo Lefresne, Alexander Benny, Negar Chooback, Ian S. Fraser
Publikováno v:
Radiotherapy and Oncology. 163:S13-S14
Publikováno v:
Clinical lung cancer. 20(5)
Introduction Second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) appear superior to first-generation TKIs in clinical trials, but at the cost of greater toxicity. It is unclear whether real-world patients, who
Autor:
I.M. Fraser, Negar Chooback, Jacqueline Regan, Robert Olson, Cheryl Ho, Shilo Lefresne, Eric Berthelet
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 135
Objectives Palliative thoracic radiotherapy (RT) can improve quality of life for patients with advanced lung cancer, but treatment can be associated with acute toxicity and symptomatic relief may take several weeks. The optimal fractionation schedule
Publikováno v:
Journal of oncology practice. 14(10)
Purpose: Patients with epidermal growth factor receptor (EGFR) mutation–positive (EGFRm) non–small-cell lung cancer commonly experience disease progression in the CNS. Here, we assess the impact of CNS disease on resource utilization and outcomes
Publikováno v:
Current Oncology
Volume 24
Issue 4
Pages 3660-338
Volume 24
Issue 4
Pages 3660-338
The 2017 Canadian Lung Cancer Conference was held 9&ndash
10 February in Vancouver, British Columbia. Each year at this prestigious event, hundreds of professionals involved in lung cancer care come together to discuss new research, to learn abo
10 February in Vancouver, British Columbia. Each year at this prestigious event, hundreds of professionals involved in lung cancer care come together to discuss new research, to learn abo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78e554b03625abd4e4ddd984ae1232e8
https://europepmc.org/articles/PMC5576474/
https://europepmc.org/articles/PMC5576474/
Autor:
M. Jones, T. Thomson, M. Martín, Y. Shen, Negar Chooback, Marco A. Marra, T. Ng, Janessa Laskin, Cheryl Ho, Katayoon Kasaian
Publikováno v:
Current Oncology
Volume 24
Issue 3
Pages 3588-254
Volume 24
Issue 3
Pages 3588-254
The most common benign salivary tumour is a pleomorphic adenoma. Transformation to malignancy, carcinoma ex pleomorphic adenoma (cxpa), occurs in 6% of cases. Management focuses on surgical resection and radiotherapy
however, rare cases require
however, rare cases require
Autor:
Daniel J. Renouf, Sophie Sun, Yaoqing Shen, Yussanne Ma, Cheryl Ho, Janessa Laskin, Howard John Lim, Negar Chooback, Stephen Yip, Yongjun Zhao, Richard D. Moore, Andrew J. Mungall, Erin Pleasance, Marco A. Marra, Erica S Tsang, Katayoon Kasaian, Diana N. Ionescu, Steven J.M. Jones, Karen Mungall, Martin L. Jones
Publikováno v:
Cold Spring Harbor Molecular Case Studies
The Personalized Onco-Genomics (POG) program at BC Cancer integrates whole-genome (DNA) and RNA sequencing into practice for metastatic malignancies. We examined the subgroup of patients with metastatic non-small-cell lung cancer (NSCLC) and report t
Autor:
Yongjun Zhao, Janessa Laskin, Cheryl Ho, Daniel J. Renouf, Marco A. Marra, Karen A. Gelmon, Negar Chooback, Howard John Lim, Andrew J. Mungall, Stephen Yip, Erica S Tsang, Steven J.M. Jones, Richard A. Moore, Yaoqing Shen
Publikováno v:
Journal of Clinical Oncology. 35:e20567-e20567
e20567 Background: Targeted therapy against driver mutations has revolutionized lung cancer management. The Personalized OncoGenomics (POG) program uses whole genome and transcriptome derived information to build pathways and identify potential thera
Autor:
Stephen Yip, Yussanne Ma, Andrew J. Mungall, Yongjun Zhao, Cheryl Ho, Steven J.M. Jones, Howard John Lim, Daniel J. Renouf, Sophie Sun, Marco A. Marra, Janessa Laskin, Negar Chooback, Richard A. Moore, Yaoqing Shen, Martin R. Jones, Erin Pleasance, Erica S Tsang
Publikováno v:
Journal of Clinical Oncology. 35:e20563-e20563
e20563 Background: The Personalized OncoGenomics (POG) program at the BC Cancer Agency integrates whole genome (DNA) and RNA sequencing into practice for metastatic malignancies. We examine patients with metastatic NSCLC and report the prevalence of